Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankur Khosla

Interventional Pain Medicine Shenandoah, TX Medical Doctor

NPI 1861760985 CMS profile 84185

255 Ed English Dr Ste C, Shenandoah, TX 77385

Open in the dashboard

General payments

$277,076

1,034 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$988,798

6 holdings reported · through program year 2025

Through program year 2025, Ankur Khosla of Shenandoah, TX is reported in the CMS Open Payments database as having received $277,076 across 1,034 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $988,798 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,467 100
2024 General $37,755 132
2023 General $50,903 140
2022 General $65,301 264
2021 General $32,338 183
2020 General $15,375 145
2019 General $5,938 70
2025 Ownership $233,998 2
2024 Ownership $218,462 1
2023 Ownership $202,492 1
2022 Ownership $187,692 1
2021 Ownership $146,154 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankur Khosla
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ankur Khosla were reported at $69,467. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ankur Khosla Interventional Pain Medicine median Middle half National median
2019 $5,938 $684 $216–$2,079 $163
2020 $15,375 $382 $122–$1,109 $114
2021 $32,338 $552 $167–$1,554 $132
2022 $65,301 $605 $187–$1,924 $149
2023 $50,903 $671 $195–$1,915 $160
2024 $37,755 $684 $206–$1,837 $164
2025 $69,467 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $78,998 378 payments
  2. SurGenTec $70,830 11 payments
  3. Spinal Simplicity, LLC $54,166 115 payments
  4. Averitas Pharma Inc. $30,510 59 payments
  5. Boston Scientific Corporation $19,067 79 payments
  6. Painteq LLC $4,317 38 payments
  7. GRT US Holding, Inc. $2,584 12 payments
  8. SI-BONE, Inc. $2,254 26 payments
  9. Medtronic USA, Inc. $2,147 32 payments
  10. Nevro Corp. $1,663 22 payments
  11. Other $10,540 262 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $90,254 18 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,318 32 payments
  3. Travel and Lodging $39,360 131 payments
  4. Food and Beverage $31,542 823 payments
  5. Royalty or License $30,726 2 payments
  6. Honoraria $22,400 12 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $9,450 4 payments
  8. Education $6,149 9 payments
  9. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $800 1 payment
  10. Entertainment $77 2 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $54,007 113 payments
  2. TiLink TiLink $34,942 2 payments
  3. Qutenza $33,094 71 payments
  4. TiLink Orthopedic $25,856 5 payments
  5. PROCLAIM Structural Heart $24,652 20 payments
  6. PROCLAIM Neuromodulation $20,949 62 payments
  7. PROCLAIM Neuromodulation $18,044 109 payments
  8. ION $11,784 2 payments
  9. ION Facet Screw System $8,822 2 payments
  10. SUPERION $7,723 21 payments
  11. Other $59,352 683 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,301

Median for Anesthesiology: 322

Drug cost

$72,846

Median for Anesthesiology: $8,738

Branded share of claims

22.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Potassium Generic 38 $61,478
Cephalexin Generic 226 $4,689
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 297 $2,939
Tizanidine Hcl Generic 420 $1,514
Gabapentin Generic 176 $1,350
Diclofenac Sodium Generic 22 $341
Cyclobenzaprine Hcl Generic 42 $213
Clindamycin Hcl Generic 12 $88
Tramadol Hcl Generic 17 $84
Meloxicam Generic 39 $83

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$928,428

Of which drugs: $134,181

Medicare patients

553

Average age 73

Services billed

52,866

302 women, 251 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 31%
Depression 28%
Chronic kidney disease 24%
Atrial fibrillation 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Capsaicin 8% patch, per square centimeter J7336 Office 28 45,082 $117,335
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 25 1,056 $14,603
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 166 1,083 $829

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
$18,835 — 45,082
HORIZANT
$115 — —
UBRELVY
$107 — —
QULIPTA
$107 — —
BOTOX
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

1,034 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record